Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

PRN Medication Recommendations for Acute Anxiety and Insomnia While Awaiting ECG

Primary Benzodiazepine Recommendation

  • The American College of Oncology recommends lorazepam 0.25 – 0.5 mg orally PRN as the first‑line agent for acute anxiety and insomnia in patients awaiting cardiac evaluation, because of its predictable pharmacokinetics, lack of cardiac conduction effects, and favorable safety profile 1.

  • Lorazepam may be administered orally or sublingually to achieve a faster onset of action, providing flexibility for acute symptom control 1.

  • Metabolism of lorazepam occurs exclusively via glucuronidation, resulting in minimal influence from age or hepatic impairment and eliminating concerns about cardiac conduction interactions 2.

  • In older or frail individuals, initiate the lower dose (0.25 mg) to reduce the risk of falls and excessive sedation 1.

Safety Monitoring for Benzodiazepine Use

  • When benzodiazepines are combined with other medications, start at the lowest effective dose and titrate cautiously, monitoring closely for excessive sedation 1.

  • Elderly patients have an increased risk of falls; therefore, dose reductions are advised for those ≥65 years or with compromised respiratory function 1.

  • Paradoxical agitation can occur in approximately 10 % of older adults receiving benzodiazepines; close observation is essential 2.

  • Limit benzodiazepine therapy to the shortest feasible duration (generally 2–4 weeks) to minimize tolerance and dependence 2.

Venlafaxine Taper Considerations

  • Venlafaxine carries a higher risk of inducing hypomania or mania compared with SSRIs, and abrupt discontinuation can precipitate a withdrawal syndrome characterized by anxiety and insomnia; a gradual taper is therefore recommended 3.

Alternative Non‑Benzodiazepine Options

  • Quetiapine 25 mg immediate‑release orally PRN is an alternative for patients where benzodiazepine‑related risks are a concern; it provides sedative, anxiolytic, and mood‑stabilizing effects without the same fall risk 1.

  • Quetiapine is particularly suitable when prominent hypomanic features are present, as it offers mood stabilization while benzodiazepines may theoretically disinhibit manic symptoms 1.

  • Hydroxyzine is another non‑benzodiazepine option with lower dependence potential, though it is associated with greater anticholinergic side effects 1.

Agents to Avoid in This Context

  • Midazolam should be reserved for inpatient settings with severe agitation requiring rapid control, given its higher sedation profile and typical intravenous/subcutaneous route 1.

  • Chlordiazepoxide is contraindicated in patients ≥65 years, those with hepatic impairment, or those with routine anxiety/agitation because of unpredictable metabolism and prolonged sedation risk 2.

Clinical Decision Algorithm (Key Steps)

Critical Drug Interaction Warning

  • Concurrent use of high‑dose benzodiazepines with high‑dose antipsychotics (e.g., olanzapine) has been associated with fatal outcomes; such combinations should be avoided or used only with extreme caution 4.

Post‑Initiation Monitoring

  • Before escalating the dose, confirm that insomnia has resolved and anxiety is adequately controlled without oversedation 1.

  • In older patients, perform daily reassessment for oversedation, ataxia, and paradoxical reactions while on any benzodiazepine 2.